Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Enterome’s lead OncoMimics™ immunotherapy, EO2463, for the treatment of follicular lymphoma (FL) in the low-tumor-burden “watch-and-wait” setting. This designation recognizes EO2463’s promising safety and efficacy profile and accelerates its path toward potential market approval. The therapy represents a new generation of microbiome-derived cancer immunotherapies designed using AI-powered molecular mimicry technology.
Science Significance
EO2463 is a first-in-class OncoMimics™ active immunotherapy combining four synthetic microbial-derived peptides that mimic B-cell lineage markers—CD20, CD22, CD37, and CD268 (BAFF receptor)—plus the helper peptide UCP2. This innovative design harnesses pre-existing CD8 T-cell responses to eliminate malignant B lymphocytes while minimizing toxicity. Built from Enterome’s 23-million-gene bacterial database, EO2463 leverages AI and machine learning to identify bacterial peptides that closely mirror tumor antigens, triggering strong, specific, and durable anti-tumor immunity. The therapy’s off-the-shelf, subcutaneous administration and excellent safety profile make it a potentially disruptive player in hemato-oncology immunotherapy.
Regulatory Significance
The Fast Track designation provides EO2463 with enhanced communication channels with the FDA, rolling review, and potential priority review eligibility, expediting regulatory timelines. Enterome plans to launch a registrational Phase 3 trial in 2026 targeting follicular lymphoma patients in the “watch-and-wait” phase—an unmet medical need where no active treatment is currently standard. This recognition positions EO2463 among the select few microbiome-derived therapeutics to achieve Fast Track status, marking a milestone in regulatory validation for Enterome’s OncoMimics™ platform.
Business Significance
Advertisement
The Fast Track milestone solidifies Enterome’s position as a leader in microbiome-based immunotherapies. EO2463’s progress could attract strategic partnerships and investment, strengthening the company’s pipeline across solid tumors and hematologic malignancies. With 230+ patients already treated across clinical programs showing robust immunogenicity and no cytokine release syndrome (CRS), Enterome is well positioned for commercial scalability. The company’s AI-driven peptide discovery engine, combined with its efficient manufacturing and distribution model, could give it a competitive edge in the rapidly expanding biopharma immuno-oncology market.
Patients’ Significance
For patients with low-tumor-burden follicular lymphoma, EO2463 could represent the first active treatment option before symptoms appear—potentially delaying progression and reducing psychological distress associated with “watchful waiting.” Its excellent tolerability and non-toxic immunotherapy mechanism could dramatically improve quality of life compared to chemotherapy or antibody-based treatments. If successful, EO2463 may redefine early-stage management in indolent non-Hodgkin lymphoma, transforming the therapeutic landscape for thousands of patients worldwide.
Policy Significance
The FDA’s move underscores the growing policy emphasis on accelerating novel cancer therapies that address unmet clinical needs. It aligns with global oncology priorities encouraging precision medicine and immunotherapy innovation. Fast Track programs like this not only reduce development timelines but also incentivize translational microbiome research—bridging AI-driven discovery, clinical relevance, and regulatory support in advancing patient-centered cancer care.
Enterome’s EO2463 and its OncoMimics™ platform embody the next frontier in AI-enabled, microbiome-based immunotherapy. By earning FDA Fast Track designation, the company stands at the intersection of scientific innovation and regulatory momentum, setting the stage for a potential paradigm shift in early-stage lymphoma management. With Phase 3 trials planned for 2026, Enterome continues to redefine the boundaries of synthetic immunology and personalized cancer therapy.
Source: Enterome press release
